Drugs / JNJ-27548547
JNJ-27548547
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04729205 | Jan 2021 → Sep 2023 | cancer, intraepithelial neoplasia | Lipomedix Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03823989 | Jan 2019 → Oct 2021 | cancer, metastatic neoplasm | Lipomedix Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01705002 | Oct 2012 → Nov 2017 | colorectal cancer | Lipomedix Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06478862 | Jun 2024 → Jan 2026 | ovarian cancer, pancreatic ductal adenocarcinoma | Lipomedix Pharmaceuticals Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-27548547 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297496 ↗ |
| Known as | Mmc lipid-based prodrug (mlp) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297496 ↗ |
| Known as | PL-MLP | “pegylated liposomal mitomycin C lipid-based prodrug (PL-MLP)” NCT01705002 ↗ |
| Known as | Promitil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06478862 ↗ |
| Modality | Other / unclassified | “pegylated liposomal mitomycin C lipid-based prodrug” NCT01705002 ↗ |
| Route | Intravenous | “PROMITIL will be administered as an intravenous infusion.” NCT01705002 ↗ |